论文部分内容阅读
目的:观察骨痿方对糖尿病骨质疏松症脾肾两虚兼血瘀证患者骨密度(BMD)的影响,并探讨其作用机制。方法:将符合纳入标准的糖尿病骨质疏松症60例(脾肾两虚兼血瘀证)患者随机分为治疗组和对照组各30例。对照组采用碳酸钙D3片口服治疗,治疗组在对照组治疗的基础上加服骨痿方治疗。疗程均为3个月,观察2组治疗前后症状、体征、血清骨特异性碱性磷酸酶(BAP)、骨密度(BMD)的变化。结果:总有效率治疗组为90.00%,对照组为66.67%,2组比较,差异有统计学意义(P<0.05);2组治疗后均能增加骨密度值,降低BAP水平,治疗组改善优于对照组,差异均有统计学意义(P<0.05)。结论:骨痿方可以改善糖尿病骨质疏松症患者的临床症状,降低BAP水平,增加骨密度值,其改善骨密度可能与其降低BAP水平有关。
Objective: To observe the effect of Gushengfangfang on bone mineral density (BMD) in patients with diabetic osteoporosis and spleen-kidney deficiency syndrome and blood-stasis syndrome and to explore its mechanism. Methods: Sixty cases of diabetic osteoporosis (spleen and kidney deficiency and blood stasis syndrome) were enrolled in this study. All patients were randomly divided into treatment group (n = 30) and control group (n = 30). The control group was treated with calcium carbonate D3 tablets orally, and the treatment group was treated with “Gubi Wei prescription” on the basis of the control group. The course of treatment was 3 months. The changes of symptoms, signs, serum Bone-specific alkaline phosphatase (BAP) and bone mineral density (BMD) were observed before and after treatment in both groups. Results: The total effective rate was 90.00% in the treatment group and 66.67% in the control group. There was significant difference between the two groups (P <0.05). After treatment, both groups could increase the BMD, decrease the BAP level and improve the treatment group The difference was statistically significant (P <0.05). Conclusion: Gushen formula can improve clinical symptoms, reduce BAP level and increase BMD in diabetic patients with osteoporosis, which may be related to the decrease of BAP level.